Bengaluru – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced the launch of its oral semaglutide biosimilar, indicated for type 2 diabetes mellitus. Dr. Reddy’s oral semaglutide is available in tablet form under the brand name Obeda® in India. This launch follows Dr. Reddy’s recent generic Semaglutide injection launches in India and Canada, further establishing the company’s position as a full‑stack player in GLP‑1 therapies.
As per the ICMR INDIAB study, India represents one of the world’s largest diabetes burdens with over 101 million adults living with the condition and a prevalence of 11.4%. Alarmingly, nearly 136 million individuals are prediabetic, and close to 40% of adults have abdominal obesity, placing them at high risk of progression . Despite multiple treatment options, uncontrolled type 2 diabetes remains a significant challenge. Oral semaglutide, a Glucagon-Like Peptide-1 receptor agonist (GLP-1 RA), is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It can offer convenient, and flexible option which may support earlier treatment initiation, improving adherence and helping reduce the risk of long term complications .
Dr. Reddy’s Obeda® (semaglutide tablets) is formulated using recombinant DNA (rDNA) origin of semaglutide active pharmaceutical ingredient (API). Dr. Reddy’s obtained approval for its oral semaglutide biosimilar from the CDSCO following a review of a Phase III clinical study enrolling 288 participants with type 2 diabetes mellitus conducted in India, which demonstrated non-inferior efficacy and a safety profile comparable to the innovator oral drug. Similar results were seen for fasting and post-prandial plasma glucose, weight loss, and overall glycemic control, as measured by the proportion of participants achieving an HbA1c level below 7% at 12 and 24 weeks. Further, no anti-drug antibodies were detected, and the immunogenicity profile was comparable to that of the innovator drug .
Dr. Reddy’s Obeda® (semaglutide tablets) is available in 3 mg, 7 mg and 14 mg strengths and recommended for once-daily oral use. It is priced at Rs. 99, Rs. 135, and Rs. 225 per tablet for the 3 mg, 7 mg, and 14 mg doses, respectively.
Leave a Reply